Insights

Innovative Technology Platform Vast Therapeutics leverages a unique nitric oxide-based antimicrobial platform that offers potential advantages over traditional antibiotics, targeting respiratory diseases with aerosolized therapies. This innovative approach creates opportunities to partner with pharmaceutical companies seeking advanced anti-infective solutions.

Focused Clinical Development The company is actively progressing towards clinical trials for its flagship inhalation therapy ALX1, indicating a readiness to engage with healthcare providers, clinical research organizations, and investors interested in emerging respiratory treatments.

Strategic Leadership Expansion Recent appointments of key medical personnel such as the Chief Medical Officer and Medical Directors signal strengthening clinical expertise and operational capabilities, opening doors for collaborations with key opinion leaders and academic institutions.

Strong Investor Support Initial funding from Shionogi highlights investor confidence in Vast’s anti-infective platform, suggesting the company is a promising partner for future co-investment opportunities, licensing deals, or strategic alliances in biotech and pharmaceutical markets.

Emerging Market Position With a niche focus on respiratory infections and chronic inflammation, alongside existing funding and development momentum, Vast offers sales prospects in specialty respiratory care and biotech sectors, particularly targeting pharmaceutical companies developing inhalation therapies.

Vast Therapeutics Tech Stack

Vast Therapeutics uses 8 technology products and services including MySQL, Babel, core-js, and more. Explore Vast Therapeutics's tech stack below.

  • MySQL
    Database
  • Babel
    Development
  • core-js
    Javascript Libraries
  • Lightbox
    Javascript Libraries
  • PHP
    Programming Languages
  • reCAPTCHA
    Security
  • Adobe Fonts
    Web Fonts
  • Apache
    Web Servers

Media & News

Vast Therapeutics's Email Address Formats

Vast Therapeutics uses at least 1 format(s):
Vast Therapeutics Email FormatsExamplePercentage
FLast@vasttherapeutics.comJDoe@vasttherapeutics.com
100%

Frequently Asked Questions

Where is Vast Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Vast Therapeutics's main headquarters is located at 4222 Emporer Boulevard Suite 470 Durham, North Carolina 27703 United States. The company has employees across 1 continents, including North America.

What is Vast Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Vast Therapeutics's official website is vasttherapeutics.com and has social profiles on LinkedIn.

What is Vast Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Vast Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Vast Therapeutics have currently?

Minus sign iconPlus sign icon
As of April 2026, Vast Therapeutics has approximately 11 employees across 1 continents, including North America. Key team members include Chief Medical Officer: P. B.Vp Of Product Development: J. S.Chairman: N. H.. Explore Vast Therapeutics's employee directory with LeadIQ.

What industry does Vast Therapeutics belong to?

Minus sign iconPlus sign icon
Vast Therapeutics operates in the Biotechnology Research industry.

What technology does Vast Therapeutics use?

Minus sign iconPlus sign icon
Vast Therapeutics's tech stack includes MySQLBabelcore-jsLightboxPHPreCAPTCHAAdobe FontsApache.

What is Vast Therapeutics's email format?

Minus sign iconPlus sign icon
Vast Therapeutics's email format typically follows the pattern of FLast@vasttherapeutics.com. Find more Vast Therapeutics email formats with LeadIQ.

When was Vast Therapeutics founded?

Minus sign iconPlus sign icon
Vast Therapeutics was founded in 2017.

Vast Therapeutics

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Vast is a preclinical airway immunology company focused on breaking the vicious cycle of infection and chronic inflammation in respiratory diseases.

The Vast technology platform begins with the unmatched antimicrobial activity of nitric oxide in the form of stable prodrugs.  When our new chemical entities are combined with inhalation formulation expertise and proprietary chemistry for delivering drug candidates to the lungs, the result is aerosolized therapies targeting the specific needs of individual patient populations.   

Nitric oxide is an endogenous molecule that plays a vital role in the natural immune system response to microbial pathogens.  Taking cues from human physiology, our nitric oxide based “antibiotic alternative” compounds are not susceptible to antimicrobial resistance mechanisms common to traditional antibiotics.

Section iconCompany Overview

Headquarters
4222 Emporer Boulevard Suite 470 Durham, North Carolina 27703 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Vast Therapeutics's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Vast Therapeutics's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.